Comparative Pharmacology
Head-to-head clinical analysis: FYARRO versus TORISEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYARRO versus TORISEL.
FYARRO vs TORISEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYARRO (sirolimus protein-bound particles for injectable suspension) is an mTOR inhibitor. Sirolimus binds to FKBP-12 and inhibits mTOR complex 1 (mTORC1), reducing phosphorylation of downstream effectors such as S6K1 and 4E-BP1, thereby inhibiting cell growth, proliferation, and angiogenesis.
Temsirolimus, a selective inhibitor of mammalian target of rapamycin (mTOR), forms a complex with FKBP-12, which binds to and inhibits mTOR kinase activity, thereby blocking signaling pathways involved in cell growth, proliferation, and angiogenesis.
Recommended dose is 100 mg/m² (up to 200 mg maximum) administered as an intravenous infusion over 30 minutes once weekly on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.
25 mg intravenously over 30-60 minutes once weekly.
None Documented
None Documented
Approximately 53 hours (terminal elimination half-life), supporting once-weekly IV administration.
Terminal elimination half-life of temsirolimus is approximately 17.3 hours (range: 11 to 26 hours). For its active metabolite sirolimus, half-life is about 15 hours (range: 10 to 30 hours). Steady-state is reached within 1 week.
Primarily via biliary/fecal excretion (approximately 77% of the dose recovered in feces as metabolites); renal excretion accounts for approximately 18%.
Primarily fecal (78%), with renal elimination accounting for 4.6% of the administered dose. Less than 5% of the dose is excreted unchanged in urine or feces.
Category C
Category C
mTOR Inhibitor
mTOR Inhibitor